Empirical antifungal therapy for patients with neutropenia and persistent fever: Systematic review and meta-analysis

European Journal of Cancer

Volumn 44, Issue 15, 2008, Pages 2192-2203

  Goldberg, Elad ^a,b   Gafter Gvili, Anat ^a,b   Robenshtok, Eyal ^a,b   Leibovici, Leonard ^a,b   Paul, Mical ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Antifungal; Azole; Echinocandin; Febrile neutropenia; Invasive fungal infections; Polyene

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; INTRALIPID; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; PLACEBO; PYRROLE; VORICONAZOLE;

ADVERSE OUTCOME; ARTICLE; CANCER PATIENT; CANCER RISK; CAUSE OF DEATH; CLINICAL TRIAL; CONFIDENCE INTERVAL; DATA EXTRACTION; DRUG EFFICACY; DRUG FORMULATION; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; HEMATOLOGIC MALIGNANCY; HIGH RISK PATIENT; HUMAN; HYPOKALEMIA; INVASIVE FUNGAL INFECTION; META ANALYSIS; MYCOSIS; NEPHROTOXICITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY CONTROL; RISK FACTOR; SOLID TUMOR; SYSTEMATIC REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME;

ANTIFUNGAL AGENTS; FEVER; HUMANS; IMMUNOCOMPROMISED HOST; NEOPLASMS; NEUTROPENIA; OPPORTUNISTIC INFECTIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 54849140300     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2008.06.040     Document Type: Article

References (59)

1. Hughes W.T., Armstrong D., Bodey G.P., et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34 (2002) 730-751
2. Link H., Bohme A., Cornely O.A., et al. Antimicrobial therapy of unexplained fever in neutropenic patients-guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society).;. Ann Hematol 82 Suppl. 2 (2003) S105-117
3. Marchetti O., Cordonnier C., and Calandra T. Empirical antifungal therapy in neutropaenic cancer patients with persistent fever. Eur J Cancer Supp 5 (2007) 32-42
4. Mahfouz T., and Anaissie E. Prevention of fungal infections in the immunocompromised host. Curr Opin Investig Drugs 4 (2003) 974-990
5. Corey L., and Boeckh M. Persistent fever in patients with neutropenia. N Engl J Med 346 (2002) 222-224
6. Walsh T., Rubin M., and Pizzo P. Respiratory diseases in patients with malignant neoplasms. In: Shelhamer J., Pizzo P.A., Parrillo J.E., et al. (Eds). Respiratory disease in the immunocompromised host (1991), JB Lippincott, Philadelphia 640-663
7. Pennington J.E. Successful treatment of aspergillus pneumonia in hematologic neoplasia. N Engl J Med 295 (1976) 426-427
8. Verfaillie C., Weisdorf D., Haake R., et al. Candida infections in bone marrow transplant recipients. Bone Marrow Transplant 8 (1991) 177-184
9. Walsh T.J. Role of surveillance cultures in prevention and treatment of fungal infections. NCI Monogr (1990) 43-45
10. Burke P.J., Braine H.G., Rathbun H.K., et al. The clinical significance and management of fever in acute myelocytic leukemia. Johns Hopkins Med J 139 (1976) 1-12
11. Stein R.S., Kayser J., and Flexner J.M. Clinical value of empirical amphotericin B in patients with acute myelogenous leukemia. Cancer 50 (1982) 2247-2251
12. Goldstone A.H., and O'driscoll A. Early AmBisome in febrile neutropenia in patients with haematological disorders. Bone Marrow Transplant 14 Suppl. 5 (1994) S15-S17
13. Pizzo P.A., Robichaud K.J., Gill F.A., et al. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 72 (1982) 101-111
14. Fukuda M., Hirashima K., Kurane R., et al. Empiric therapy with fluconazole in granulocytopenic patients with carcinoma or leukemia. Jpn J Antibiot 47 (1994) 1065-1070
15. EORTC International Antimicrobial Therapy Cooperative Group. Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med 86 (1989) 668-672
16. Gotzsche P.C., and Johansen H.K. Routine versus selective antifungal administration for control of fungal infections in patients with cancer. Cochrane Database Syst Rev (2002) CD000026
17. Walsh T.J., Pappas P., Winston D.J., et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 346 (2002) 225-234
18. Jorgensen K.J., Gotzsche P.C., and Johansen H.K. Voriconazole versus amphotericin B in cancer patients with neutropenia. Cochrane Database Syst Rev (2006) CD004707
19. Cochrane handbook for systematic reviews of interventions 4.2.6, Updated September 2006. http://www.cochrane.org.
20. Moher D., Pham B., Jones A., et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 352 (1998) 609-613
21. Ascioglu S., Rex J.H., De Pauw B., et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 34 (2002) 7-14
22. Higgins J.P., Thompson S.G., Deeks J.J., et al. Measuring inconsistency in meta-analyses. Bmj 327 (2003) 557-560
23. Wendel F., Jenett M., Geib A., et al. Low-dose CT in neutropenic patients with fever of unknown origin. Rofo 177 (2005) 1424-1429
24. Stemmer S.M., Maor Y., and Hardan I. Oral fluconazole for empiric treatment of prolonged Fever in neutropenic patients: prospective study in 250 consecutive patients after stem cell transplantation. Am J Clin Oncol 27 (2004) 328-332
25. Pascual B., Ayestaran A., Montoro J.B., et al. Administration of lipid-emulsion versus conventional amphotericin B in patients with neutropenia. Ann Pharmacother 29 (1995) 1197-1201
26. Maertens J., Theunissen K., Verhoef G., et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 41 (2005) 1242-1250
27. Leenders A.C., Daenen S., Jansen R.L., et al. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haematol 103 (1998) 205-212
28. Eriksson U., Seifert B., and Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. Bmj 322 (2001) 579-582
29. Ellis M., Spence D., De Pauw B., et al. An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin Infect Dis 27 (1998) 1406-1412
30. Cisneros J.M., Espigado I., Rivero A., et al. Empirical antifungal therapy in selected patients with persistent fever and neutropenia. Enferm Infecc Microbiol Clin 23 (2005) 609-614
31. Anaissie E.J., Darouiche R.O., Abi-Said D., et al. Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis 23 (1996) 964-972
32. Wingard J.R., Vaughan W.P., Braine H.G., et al. Prevention of fungal sepsis in patients with prolonged neutropenia: a randomized, double-blind, placebo-controlled trial of intravenous miconazole. Am J Med 83 (1987) 1103-1110
33. Schiel X., Link H., Maschmeyer G., et al. A prospective, randomized multicenter trial of the empirical addition of antifungal therapy for febrile neutropenic cancer patients: Results of the Paul Ehrlich Society for Chemotherapy (PEG) Multicenter Trial II. Infection 34 (2006) 118-126
34. Cordonnier C., Pautas C., Maury S., et al. Empirical versus pre-emptive antifungal therapy in high-risk febrile neutropenic patients: A prospective randomized study. ASH Annual Meeting Abstracts 108 (2006) 2019
35. Winston D.J., Hathorn J.W., Schuster M.G., et al. A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. Am J Med 108 (2000) 282-289
36. Walsh T.J., Rubin M., Hathorn J., et al. Amphotericin B vs high-dose ketoconazole for empirical antifungal therapy among febrile, granulocytopenic cancer patients. A prospective, randomized study. Arch Intern Med 151 (1991) 765-770
37. Viscoli C., Castagnola E., Van Lint M.T., et al. Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicentre, prospective and randomised clinical trial. Eur J Cancer 32A (1996) 814-820
38. Silling G., Fegeler W., Roos N., et al. Early empiric antifungal therapy of infections in neutropenic patients comparing fluconazole with amphotericin B/flucytosine. Mycoses 42 Suppl. 2 (1999) 101-104
39. Schuler U., Bammer S., Aulitzky W.E., et al. Safety and efficacy of itraconazole compared to amphotericin B as empirical antifungal therapy for neutropenic fever in patients with haematological malignancy. Onkologie 30 (2007) 185-191
40. Malik I.A., Moid I., Aziz Z., et al. A randomized comparison of fluconazole with amphotericin B as empiric anti-fungal agents in cancer patients with prolonged fever and neutropenia. Am J Med 105 (1998) 478-483
41. Fainstein V., Bodey G.P., Elting L., et al. Amphotericin B or ketoconazole therapy of fungal infections in neutropenic cancer patients. Antimicrob Agents Chemother 31 (1987) 11-15
42. Cornely O., Reichert D., Buchheidt D., et al. Three-armed multicenter randomized study on the empiric treatment of neutropenic fever in a high risk patient population (PEG Study III). Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother 41 (2001) 16-19
43. Boogaerts M., Winston D.J., Bow E.J., et al. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann Intern Med 135 (2001) 412-422
44. Sandler E.S., Mustafa M.M., Tkaczewski I., et al. Use of amphotericin B colloidal dispersion in children. J Pediatr Hematol Oncol 22 (2000) 242-246
45. Wingard J.R., White M.H., Anaissie E., et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin Infect Dis 31 (2000) 1155-1163
46. White M.H., Bowden R.A., Sandler E.S., et al. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis 27 (1998) 296-302
47. Walsh T.J., Finberg R.W., Arndt C., et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 340 (1999) 764-771
48. Subira M., Martino R., Gomez L., et al. Low-dose amphotericin B lipid complex vs conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies--a randomized, controlled trial. Eur J Haematol 72 (2004) 342-347
49. Schoffski P., Freund M., Wunder R., et al. Safety and toxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin: randomised study. Bmj 317 (1998) 379-384
50. Prentice H.G., Hann I.M., Herbrecht R., et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 98 (1997) 711-718
51. Nucci M., Loureiro M., Silveira F., et al. Comparison of the toxicity of amphotericin B in 5% dextrose with that of amphotericin B in fat emulsion in a randomized trial with cancer patients. Antimicrob Agents Chemother 43 (1999) 1445-1448
52. Moreau P., Milpied N., Fayette N., et al. Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with intralipid compared with conventional amphotericin B in neutropenic patients. J Antimicrob Chemother 30 (1992) 535-541
53. Fleming R.V., Kantarjian H.M., Husni R., et al. Comparison of amphotericin B lipid complex (ABLC) vs ambisome in the treatment of suspected or documented fungal infections in patients with leukemia. Leuk Lymphoma 40 (2001) 511-520
54. Caillot D., Reny G., Solary E., et al. A controlled trial of the tolerance of amphotericin B infused in dextrose or in Intralipid in patients with haematological malignancies. J Antimicrob Chemother 33 (1994) 603-613
55. Walsh T.J., Teppler H., Donowitz G.R., et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 351 (2004) 1391-1402
56. . Maertens J, Madero L, Reilly A, et al. Randomized, double blind, multicenter trial of caspofungin (CAS) versus (vs) liposomal amphotericin B (LAMB) for empirical antifungal therapy (EAFRx) of pediatric patients (pts) with persistent fever & neutropenia (PFN). 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 2007; Abstract M-621.
57. Rijnders B.J., Cornelissen J.J., Slobbe L., et al. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin Infect Dis 46 (2008) 1401-1408
58. Robenshtok E., Gafter-Gvili A., Goldberg E., et al. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation:Systematic review and meta-analysis. J Clin Oncol 25 (2007) 5471-5489
59. Hebart H., Klingspor L., Klingebiehl T., et al. PCR-based liposomal amphotericin B treatment following allogeneic stem cell transplantation is a safe treatment strategy: Preliminary results of a prospective study. Blood (ASH Annual Meeting Abstracts) 104 (2004) 192